In this article, Karch, Temple and colleagues describe a resource of fibroblasts, patient-derived induced pluripotent stem cells, and genome engineered stem cells with comprehensive clinical histories that can be accessed by the scientific community for disease modeling and development of novel therapeutics for primary tauopathies.
- corticobasal degeneration
- frontotemporal dementia
- induced pluripotent stem cells
- neural progenitor cells
- progressive supranuclear palsy